NOTICE For Investors In ABT: Lawsuit against Abbott Laboratories announced by Shareholders Foundation

San Diego, California--(Newsfile Corp. - November 29, 2022) - The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Abbott Laboratories (NYSE: ABT).

Investors who purchased Abbott Laboratories (NYSE: ABT) shares prior to February 2021 and continue to hold any of their NYSE: ABT shares have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On August 31, 2022, a lawsuit was filed for certain investors in NYSE: ABT shares against Abbott Laboratories over alleged Violations of Securities Laws. The plaintiff alleges that the Defendants made numerous materially false and misleading statements and omissions concerning what the U.S. Food and Drug Administration ("FDA") called "egregiously unsanitary" conditions at the Company's Sturgis facility, and that the Defendants repeatedly touted to investors the safety and salability of Abbott's infant formula brands and their contribution to the Company's sales and revenue growth.

Those who purchased Abbott Laboratories (NYSE: ABT) shares should contact the Shareholders Foundation, Inc.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/146009